Navigation Links
Cell Therapeutics, Inc. Announces Exercise of Overallotment
Date:7/23/2009

SEATTLE, July 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) ("CTI" or the "Company") today announced that the underwriter of its previously announced public offering of 29,332,107 shares of its common stock and warrants to purchase up to 7,333,027 shares of its common stock has exercised in full its option to purchase 4,399,816 additional shares of its common stock and warrants to purchase up to 1,099,954 additional shares of its common stock to cover overallotments. The exercise of the underwriter's overallotment option results in the issuance in this offering of an aggregate of 33,731,923 shares of its common stock and warrants to purchase up to 8,432,981 shares of its common stock, for aggregate gross proceeds of approximately $43.9 million. The net proceeds to the Company after deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $40.3 million.

Each warrant has an exercise price of $1.70 per warrant share, for total potential additional gross proceeds to the Company of approximately $14.3 million upon exercise of the warrants. The warrants are exercisable immediately upon the date of issuance and will expire nine months thereafter.

As previously announced, the Company expects to close the offering on or about July 28, 2009, subject to customary conditions, at which time the Company will receive the cash proceeds from the offering and deliver the securities.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as sole book-running manager for the offering. In addition, Trout Capital LLC acted as financial advisor to the Company. The offering was conducted as a public offering pursuant to the Company's shelf registration statement
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
2. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
3. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
4. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
8. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
9. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
10. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
11. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... December 12, 2014 Trend lines for ... overall global economic growth, Eugene Arthurs, CEO of ... said in a featured talk at OPTIC (Optics and ... the National Chung Hsing University in Taichung. , As ... into future energy supplies and soon to hit US$50 ...
(Date:12/13/2014)... Charlotte, NC (PRWEB) December 13, 2014 ... nearly 3 million people between now and 2030." If ... will become the seventh most populous state in the ... Commerce is gathering at the Future of North Carolina ... We Ready? Do we have the necessary infrastructure in ...
(Date:12/13/2014)... , Dec. 12, 2014  Vermillion, Inc. (NasdaqCM: VRML), a ... the appointments of Veronica G. H. Jordan , ... Company,s Board of Directors, bringing the total number of ... Jim LaFrance , Chairman, President, and ... pleased to announce the appointments of Veronica and David ...
(Date:12/13/2014)... Dec. 12, 2014  Vaccinex Inc., a ... and development of therapeutic monoclonal antibodies to ... publication of a manuscript entitled "SEMA4D compromises ... in neurodegenerative disease" in the January 2015 ... The publication highlights an important role for ...
Breaking Biology Technology:Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2
... Fair Political,Practices Commission, SANTA MONICA, Calif., Nov. 21 ... resign from the board for,violating conflict of interest rules, ... Reed intervened and attempted to influence the awarding ... Burnham Institute, where Reed is,president and chief executive., ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... during the 19th Annual Piper Jaffray,Health Care Conference ... Eastern,Time. The presentation will be webcast from The ... the Investor Relations tab at http://www.alexza.com ,or ...
... Incorporated,(Nasdaq: VPHM ) today announced that Vincent ... of ViroPharma, will present,at the Lazard Capital Markets ... Tuesday, November 27, 2007. The conference is being ... also announced that Michel de Rosen, president and ...
Cached Biology Technology:California Stem Cell Board Member Violates Conflict Rules; Should Resign From Committee, Consumer Group Says 2California Stem Cell Board Member Violates Conflict Rules; Should Resign From Committee, Consumer Group Says 319th Annual Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation 2ViroPharma to Present at Two Upcoming Healthcare Conferences 2
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... or nurture? It's the eternal question for so many ... may play a larger role than nurture when it ... , Researchers from the University of Texas at Austin ... on 674 families, each with a same-sex adolescent pair, ...
... breast cancer , A team from the University of ... a cancer vaccine based on the bacterium Listeria monocytogenes, ... vaccines, which are more properly described as immunotherapy, work ... , Using Listeria, the researchers, led by Yvonne Paterson, ...
... are being designed to battle cancer, but their use ... established tumors require tumor-reactive T cells to traffic to ... there in order to kill cancer cells. A problem ... once they reach the environment surrounding the tumor. This ...
Cached Biology News:Environment, not genes, key in family relationships 2Breast tumors in mice eradicated using cancer vaccine 2Breast tumors in mice eradicated using cancer vaccine 3
...
... APAgene kits are designed to rapidly and ... our patented APA Technology. APAgene provides hassle-free, ... price. All necessary ingredients are provided in ... can be used for insert-end amplification of ...
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: